Can you provide an overview of novel cefepime-based beta‑lactam/beta‑lactamase inhibitor combinations?

Overview of Novel Cefepime-Based β-Lactam/β-Lactamase Inhibitor Combinations

Novel cefepime-based β-lactam/β-lactamase inhibitor (BL/BLI) combinations represent a critical advancement in treating multidrug-resistant Gram-negative infections, with four key agents—cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, and cefepime/nacubactam—each offering distinct resistance coverage profiles that should guide pathogen- and mechanism-specific selection.

Core Agents and Their Distinct Mechanisms

Cefepime/Enmetazobactam (FEP/EMT)

This combination targets ESBL-producing and AmpC-producing Enterobacterales through enmetazobactam's activity against CTX-M, TEM, and SHV class A β-lactamases 1, 2. The FDA has approved this agent for complicated urinary tract infections (cUTI), hospital-acquired pneumonia including ventilator-associated pneumonia, and bacteremia 2.

• Primary indication: Carbapenem-sparing strategy for ESBL infections
• Additional coverage: OXA-48-like carbapenemases when susceptibility confirmed 2, 3
• Clinical superiority: Demonstrated better outcomes than piperacillin/tazobactam in phase 3 trials 2

Cefepime/Taniborbactam (FTB)

This bicyclic boronate inhibitor provides the broadest β-lactamase coverage, including serine β-lactamases (classes A, C, D) and critically, metallo-β-lactamases (MBLs) including NDM and VIM, but notably not IMP 4.

• Resistance coverage: Carbapenem-resistant Enterobacterales (CRE), including MBL-producers (NDM, VIM)
• Activity against resistant strains: Effective against ceftazidime-avibactam-resistant, meropenem-vaborbactam-resistant, and ceftolozane-tazobactam-resistant organisms 4
• MIC reduction: Achieved >64-fold MIC90 reduction versus cefepime alone in >13,000 Enterobacterales isolates 4
• Phase 3 data: Superior to meropenem for cUTI caused by Enterobacterales and P. aeruginosa 5, 4

Cefepime/Zidebactam (FPZ)

This agent employs a dual mechanism: β-lactamase inhibition plus β-lactam enhancement through PBP2 binding 1, 6.

• Unique advantage: Retains activity against XDR Enterobacterales and P. aeruginosa, including cefiderocol-resistant and aztreonam/avibactam-resistant strains 1
• Resistance mechanism: The PBP2 binding provides activity even when β-lactamase inhibition alone is insufficient 6
• Potential role: Last-line option for extensively resistant organisms 3

Cefepime/Nacubactam (FEP/NAC)

This combination shows promise against carbapenem-producing and MBL-producing strains, though clinical data remain limited 1.

Clinical Decision Algorithm

For ESBL-Producing Enterobacterales

Use cefepime/enmetazobactam as first-line carbapenem-sparing therapy 2, 3. This approach is supported by FDA approval and phase 3 superiority data over piperacillin/tazobactam.

For Carbapenem-Resistant Enterobacterales (Non-MBL)

Select cefepime/taniborbactam when dealing with serine carbapenemases (KPC, OXA-48) resistant to existing BL/BLI agents 4, 3. The >64-fold MIC reduction demonstrates potent activity.

For MBL-Producing Enterobacterales or P. aeruginosa

Choose between:

• Cefepime/taniborbactam for NDM or VIM producers 4, 3
• Cefepime/zidebactam when resistance to other novel agents exists or for IMP producers (since taniborbactam lacks IMP activity) 1, 6
• Aztreonam/avibactam remains an alternative per ESCMID guidelines for severe CRE infections with MBLs 7

For Extensively Drug-Resistant (XDR) Organisms

Prioritize cefepime/zidebactam given its retained activity against cefiderocol-resistant and aztreonam/avibactam-resistant strains through its dual PBP2-binding mechanism 1, 6.

Critical Pharmacokinetic Considerations

All cefepime-based combinations share similar PK profiles with cefepime itself 4:

• Renal clearance: Dose adjustment mandatory in renal impairment 8
• Half-life: Approximately 2-2.3 hours
• Volume of distribution: ~20L
• Infusion duration: Typically 2 hours for optimal PK/PD targets 4

Major Clinical Caveats

Neurotoxicity Risk

Cefepime carries significant neurotoxicity risk, including encephalopathy, seizures, myoclonus, and nonconvulsive status epilepticus, particularly in patients with renal impairment receiving inadequate dose adjustments 8. Discontinue immediately if neurotoxicity occurs and consider hemodialysis 8.

Resistance Mechanisms Requiring Surveillance

Multiple concurrent resistance mechanisms can emerge 4:

• IMP production (not covered by taniborbactam)
• PBP3 alterations
• Porin loss and efflux pump overexpression
• Evolving KPC or NDM variants

Geographic Variability

Resistance patterns vary significantly by region, necessitating local antibiogram data and rapid molecular diagnostics for optimal agent selection 1.

Integration with Current Guidelines

The 2022 ESCMID guidelines recommend newer BL/BLI combinations (ceftazidime-avibactam, meropenem-vaborbactam) for CRE infections without requiring combination therapy when organisms are susceptible 7. Cefepime-based combinations should follow this same monotherapy approach when susceptibility is confirmed, reserving combination therapy only for severe infections with organisms resistant to monotherapy options or when MIC values approach breakpoints.

For severe CRE infections with MBLs, ESCMID suggests aztreonam plus ceftazidime-avibactam combination therapy (conditional recommendation, moderate evidence) 7. Cefepime/taniborbactam or cefepime/zidebactam may serve as single-agent alternatives to this combination, pending additional clinical validation.

Antimicrobial Stewardship Imperatives

Implement rapid molecular diagnostics to identify specific β-lactamase genes (CTX-M, KPC, NDM, VIM, OXA-48, IMP) before selecting among cefepime-based combinations 1, 3. This genotype-driven approach maximizes efficacy while minimizing inappropriate broad-spectrum use.

Perform susceptibility testing for all novel agents when available, as cross-resistance patterns are unpredictable 4. Do not assume activity based solely on β-lactamase genotype.

Current Evidence Limitations

Clinical trial data remain predominantly limited to cUTI 5, 2, 4. Evidence for severe infections (pneumonia, bacteremia, intra-abdominal infections) is emerging from real-world studies but lacks the robustness of randomized controlled trials 3. Exercise heightened vigilance when using these agents for severe infections outside cUTI, with close monitoring for clinical response and consideration of combination therapy in critically ill patients until more data emerge.